z-logo
open-access-imgOpen Access
L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution
Author(s) -
Thu H.M. Nguyen,
Patricia E. Carreira,
Francisco J. SánchezLuque,
Stephanie N. Schauer,
Allister C. Fagg,
Sandra R. Richardson,
Claire M. Davies,
J. Samuel Jesuadian,
Marie-Jeanne H.C. Kempen,
RobinLee Troskie,
Cini James,
Elizabeth A. Beaven,
Tristan P. Wallis,
Jermaine Coward,
Naven Chetty,
A. Crandon,
Deon J. Venter,
Jane E. Armes,
Lewis Perrin,
John D. Hooper,
Adam D. Ewing,
Kyle R. Upton,
Geoffrey J. Faulkner
Publication year - 2018
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2018.05.090
Subject(s) - retrotransposon , insertional mutagenesis , biology , carcinogenesis , enhancer , cancer research , ovarian cancer , mutagenesis , genetics , ovarian tumor , gene , mutation , genome , cancer , microbiology and biotechnology , gene expression , transposable element
LINE-1 (L1) retrotransposons are a source of insertional mutagenesis in tumor cells. However, the clinical significance of L1 mobilization during tumorigenesis remains unclear. Here, we applied retrotransposon capture sequencing (RC-seq) to multiple single-cell clones isolated from five ovarian cancer cell lines and HeLa cells and detected endogenous L1 retrotransposition in vitro. We then applied RC-seq to ovarian tumor and matched blood samples from 19 patients and identified 88 tumor-specific L1 insertions. In one tumor, an intronic de novo L1 insertion supplied a novel cis-enhancer to the putative chemoresistance gene STC1. Notably, the tumor subclone carrying the STC1 L1 mutation increased in prevalence after chemotherapy, further increasing STC1 expression. We also identified hypomethylated donor L1s responsible for new L1 insertions in tumors and cultivated cancer cells. These congruent in vitro and in vivo results highlight L1 insertional mutagenesis as a common component of ovarian tumorigenesis and cancer genome heterogeneity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom